Polynucleotides and Skin Boosters for the Under Eye: a Claim by Claim Evidence Ledger

The under eye has become the flagship indication for a category of injectable that did not have a consumer name three years ago. Polynucleotides, polydeoxyribonucleotides, salmon DNA, skin boosters, biostimulators. The vocabulary is unstable because the category is young, and the marketing has moved considerably faster than the evidence.

That is not an accusation. It is the normal life cycle of an aesthetic treatment, and it means the useful question is not whether polynucleotides work. It is which specific claim you are being sold and what tier of evidence sits under that particular claim, because they are not the same tier.

The original element in this piece is a claim by claim evidence ledger for injectable polynucleotides in the infraorbital area, sorting each of the four commonly made promises into the strongest study design that has actually tested it. The sorting method is stated first so you can check the work, which is more than the brochures do.

The method. For each claim, I asked what is the highest tier of published evidence that has tested this specific claim in this specific anatomic area. The tiers, in ascending order, are mechanistic and animal work, practitioner survey and perceived effectiveness, uncontrolled clinical series, and randomized controlled trial with a blinded evaluator. A claim supported only at a lower tier is not disproven. It is unproven, and those are different things, and conflating them is how patients end up disappointed rather than harmed.

Claim one, that polynucleotides thicken and improve the quality of thin under eye skin. This is the core claim and it is the best supported one, though the support is not where people assume. The mechanism is plausible and has been demonstrated at the tissue level: comparative work in animal models evaluating the biostimulatory effects of hyaluronic acid based polynucleotide preparations against other injectable classes shows measurable tissue responses rather than simple volumetric filling (Aesthetic Plastic Surgery, 2025). A 2024 review of current practice in aesthetic medicine found broadly consistent practitioner reporting of effectiveness for skin quality indications (International Journal of Molecular Sciences, 2024). So this claim sits at mechanistic plus practitioner perception. It has not been established by blinded randomized trial in the infraorbital area specifically.

Claim two, that they reduce under eye pigmentation. This is the weakest of the four and the one most aggressively marketed, because pigment is what most patients with dark circles actually have. There is no direct mechanistic pathway by which a polynucleotide preparation would reduce epidermal or dermal melanin. Any improvement in the appearance of pigment would be secondary, through improved dermal light scattering, which is a real optical effect and a small one. This claim currently sits at the bottom tier. If a clinic leads with pigment reduction, you are being sold the least supported version of the treatment, and the first thing to establish is whether pigment is even your problem. That determination is exactly what the stretch test and the three kinds of dark circles are for, and doing it before booking anything will save you more money than any product comparison.

Claim three, that they fill or reduce hollowing. They do not, and reputable practitioners do not claim they do, but the claim survives in consumer marketing because it is what people want. Polynucleotides are not volumizers. They carry negligible volume at treatment doses and are not intended to project tissue. A patient whose complaint is a true tear trough hollow, meaning a shadow cast by a step off at the orbital rim, is a candidate for a volumizing approach and not for a booster, with all the tradeoffs described in tear trough filler, what to know. Selling a booster to a hollowing patient is the most common mismatch in this category.

Claim four, that they work well in combination with other modalities. This has genuine and growing support, and it is the most interesting part of the literature. Work on combining polydeoxyribonucleotide with other biochemical and physical agents describes synergistic regenerative strategies rather than standalone use (International Journal of Molecular Sciences, 2026). The practical reading is that the category is maturing into an adjunct rather than a monotherapy, which is consistent with how practitioners actually report using it. A 2024 survey of Korean dermatologists, working in the market where these products have the longest clinical history, documented that pattern of practice directly (Journal of Cosmetic Dermatology, 2024).

What the ledger adds up to. One claim at mechanistic and perception level, one at essentially no level, one that is false as commonly stated, and one that is emerging and reasonably supported. That is a young treatment with a real signal and a marketing layer running well ahead of it. It is not a scam and it is not established care.

What the studies do not tell you, stated specifically. There is no published randomized controlled trial of injectable polynucleotides for infraorbital skin quality using a blinded evaluator and a validated infraorbital specific outcome scale. That is the missing study, and its absence is the single most important fact in this article. The scales used in the existing literature are largely global or periorbital rather than infraorbital, the follow up windows are short relative to how long patients are told results last, and comparator arms against saline or against an established alternative such as platelet rich plasma are almost entirely absent. The comparison against platelet rich plasma matters most commercially, since the two are sold to the same patient for the same complaint at similar price points, and it has not been run. What that means for the PRP side of the question is covered in PRP for under eye circles.

How to use this at a consultation. Ask which of the four claims the clinic is making for you personally, and ask it in those terms. If the answer is skin quality in a patient who has already been shown to have thin skin rather than pigment or hollowing, you are in the best supported use of the treatment and the expectations should be modest and gradual. If the answer is pigment, ask what the mechanism is meant to be, and listen for whether the answer is optical or melanin based, because only one of those is defensible. If the answer is hollowing, you are being offered the wrong product.

And ask about the treatment course honestly. These are protocols of several sessions spaced weeks apart, with maintenance, and the total cost over a year is frequently higher than the alternative the patient rejected as expensive. A category can be promising and still be the wrong purchase for you, and in the under eye the deciding factor is almost never the product. It is whether anyone correctly identified what was casting the shadow in the first place.